Key result
Type 1 diabetes with microangiopathy is linked to ~45% higher serum fibronectin levels.
Why the study?
Does type 1 diabetes mellitus with microangiopathies or obesity correlate with elevated serum fibronectin content as a marker of endothelial dysfunction in young individuals?
Cross-Sectional (n=88)
No
Does type 1 diabetes mellitus with microangiopathies or obesity correlate with elevated serum fibronectin content as a marker of endothelial dysfunction in young individuals?
Elevated serum fibronectin in young individuals with type 1 diabetes and obesity may serve as an early marker for endothelial dysfunction preceding clinical cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May indicate endothelial dysfunction in young type 1 diabetes and obesity; leaves open fibronectin’s prognostic value and requires prospective validation.
Micro- and macroangiopathies are the main causes of disability and mortality among the patients suffering from diabetes mellitus. Endothelial dysfunction is the early and important condition preceding the development of diabetic angiopathies. The serum fibronectin content may be one of the markers of endothelial dysfunction. We have documented the enhanced serum fibronectin content in the patients suffering from type 1 diabetes mellitus with concomitant microangiopathies and in the subjects presenting with obesity. The rise in the serum fibronectin level correlated with the body mass index, parameters of carbohydrate and lipid metabolism. Alteration of these parameters discovered in the present study may be used as the markers of endothelial dysfunction associated with the above pathological conditions.
No takes yet. Share an insight, caveat, or question.
L.A. Mogilnitskaya (2015) conducted a cross-sectional in Type 1 diabetes mellitus with microangiopathies and obesity (n=88). Type 1 diabetes mellitus with microangiopathies or obesity vs. Healthy controls was evaluated on Serum fibronectin content (p=<0.04). Serum fibronectin levels were elevated in patients with type 1 diabetes and microangiopathies and obese subjects compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: